These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 10438404)

  • 1. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration.
    Friedler S; Raziel A; Schachter M; Strassburger D; Bukovsky I; Ron-El R
    Hum Reprod; 1999 Aug; 14(8):1944-8. PubMed ID: 10438404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
    Weissman A; Barash A; Shapiro H; Casper RF
    Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.
    Tournaye H; Sukhikh GT; Kahler E; Griesinger G
    Hum Reprod; 2017 May; 32(5):1019-1027. PubMed ID: 28333318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study.
    Iwase A; Ando H; Toda S; Ishimatsu S; Harata T; Kurotsuchi S; Shimomura Y; Goto M; Kikkawa F
    Arch Gynecol Obstet; 2008 Apr; 277(4):319-24. PubMed ID: 17938943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
    Golan A; Herman A; Soffer Y; Bukovsky I; Caspi E; Ron-El R
    Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response.
    Emperaire JC; Parneix I; Ruffie A
    Reprod Biomed Online; 2004 Jul; 9(1):22-7. PubMed ID: 15257812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization.
    Baker VL; Jones CA; Doody K; Foulk R; Yee B; Adamson GD; Cometti B; DeVane G; Hubert G; Trevisan S; Hoehler F; Jones C; Soules M
    Hum Reprod; 2014 Oct; 29(10):2212-20. PubMed ID: 25100106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8.
    Michnova L; Dostal J; Kudela M; Hamal P; Langova K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):86-91. PubMed ID: 28323291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study.
    Friedler S; Gilboa S; Schachter M; Raziel A; Strassburger D; Ron El R
    Reprod Biomed Online; 2006 Jan; 12(1):27-32. PubMed ID: 16454930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial.
    Griesinger G; Blockeel C; Sukhikh GT; Patki A; Dhorepatil B; Yang DZ; Chen ZJ; Kahler E; Pexman-Fieth C; Tournaye H
    Hum Reprod; 2018 Dec; 33(12):2212-2221. PubMed ID: 30304457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of frozen-thawed embryos in artificially prepared cycles with and without prior gonadotrophin-releasing hormone agonist suppression: a prospective randomized study.
    Simon A; Hurwitz A; Zentner BS; Bdolah Y; Laufer N
    Hum Reprod; 1998 Oct; 13(1O):2712-7. PubMed ID: 9804219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection.
    Bergh C; Lindenberg S;
    Hum Reprod; 2012 Dec; 27(12):3467-73. PubMed ID: 23019296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.